.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Colorcon
Cipla
QuintilesIMS
Medtronic
McKesson
Chubb
Teva
Novartis
Federal Trade Commission

Generated: December 14, 2017

DrugPatentWatch Database Preview

US Patents With Foreign Priority to Sweden Patent: 9303657

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-001Aug 1, 2008RXYesYes► Subscribe► Subscribe► SubscribeYYCLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-002Aug 1, 2008RXYesYes► Subscribe► Subscribe► SubscribeYYCLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-003Nov 8, 2013RXYesYes► Subscribe► Subscribe► SubscribeYYCLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist